Prolongation of Homograft Survival in Mice with Single Doses of Cyclophosphamide

No abstract is available for this paper.

• Publication year

  1963

• Venue

  Nature

• Publication date

  1963-10-05

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/200084A0PMID 14074645
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The inhibition of hemagglutinin formation in mice by thioguanin.

  1962cited by this paper
• The effect of cytotoxic agents on the production of antibody to T.A.B. vaccine in the mouse.

  1962cited by this paper
• Effect of 6-Mercaptopurine on Antibody Production.∗

  1958cited by this paper
• The effect of guanazolo on antibody formation.

  1952cited by this paper

• The Effect of Post-Transplant Cyclophosphamide Administration on Graft-Versus-Host Disease in Allogeneic Bone Marrow Transplantation

  2026cites this paper
• Transplant oncology and anti-cancer immunosuppressants

  2025cites this paper
• Natural Killer (NK) Cell Alloreactivity in Haploidentical Stem Cell Transplantation

  2025cites this paper
• Human Leukocyte Antigen–Haploidentical Haematopoietic Stem Cell Transplantation Using Post-Transplant Cyclophosphamide for Paediatric Haematological Malignancies

  2024cites this paper
• Graft Versus Host Disease Prophylaxis in Matched Donor Stem Cell Transplantation: Post-transplantation Cyclophosphamide Combinations Versus Methotrexate/Tacrolimus.

  2024cites this paper
• Expanding post-transplant cyclophosphamide to matched unrelated donor transplants and beyond.

  2023cites this paper
• Graft-versus-host disease: teaching old drugs new tricks at less cost

  2023cites this paper
• Establishment of Chimerism and Organ Transplant Tolerance in Laboratory Animals: Safety and Efficacy of Adaptation to Humans

  2022cites this paper
• Ex vivo and in vivo T-cell depletion in allogeneic transplantation: towards less or non-cytotoxic conditioning regimens

  2022cites this paper
• The development of post-transplant cyclophosphamide: Half a century of translational team science.

  2022cites this paper
• A single-center experience of haploidentical stem cell transplantation in hematological malignancies

  2022cites this paper
• A Review of Cyclophosphamide-Induced Transplantation Tolerance in Mice and Its Relationship With the HLA-Haploidentical Bone Marrow Transplantation/Post-Transplantation Cyclophosphamide Platform

  2021cites this paper
• T-Cell-Replete Versus ex vivo T-Cell-Depleted Haploidentical Haematopoietic Stem Cell Transplantation in Children With Acute Lymphoblastic Leukaemia and Other Haematological Malignancies

  2021cites this paper
• Post‐transplant cyclophosphamide limits reactive donor T cells and delays the development of graft‐versus‐host disease in a humanized mouse model

  2021cites this paper
• Haploidentical Transplantation: Challenges and Solutions

  2021cites this paper
• Proliferation kinetics of immune cells during early phase of bone marrow transplantation in mouse model based on chemotherapy conditioning.

  2021cites this paper
• Use of Post-transplant Cyclophosphamide Treatment to Build a Tolerance Platform to Prevent Liquid and Solid Organ Allograft Rejection

  2021cites this paper
• Haploidentical Peripheral Stem Cell Transplantation for Young Patients with Severe Aplastic Anemia Using Post-Transplantation Cyclophosphamide and Methotrexate.

  2021cites this paper
• The Pathophysiology and Treatment of Graft-Versus-Host Disease: Lessons Learnt From Animal Models

  2021cites this paper
• Cyclophosphamide-Induced Tolerance in Allogeneic Transplantation: From Basic Studies to Clinical Application

  2020cites this paper
• T-Cell Replete Myeloablative Haploidentical Bone Marrow Transplantation Is an Effective Option for Pediatric and Young Adult Patients With High-Risk Hematologic Malignancies

  2020cites this paper
• Recent Advances in Haploidentical Hematopoietic Cell Transplantation for Pediatric Hematologic Malignancies

  2020cites this paper
• Key Aspects of the Immunobiology of Haploidentical Hematopoietic Cell Transplantation

  2020cites this paper
• Post-transplantation cyclophosphamide to facilitate HLA-haploidentical hematopoietic cell transplantation: Mechanisms and results.

  2019cites this paper
• T-Cell Replete Haploidentical Transplantation

  2019cites this paper
• Haploidentical Stem Cell Transplantation With Post-Transplantation Cyclophosphamide for Aggressive Lymphomas: How Far Have We Come and Where Are We Going?

  2019cites this paper
• The European Society for Blood and Marrow Transplantation (EBMT) consensus recommendations for donor selection in haploidentical hematopoietic cell transplantation

  2019cites this paper
• Utilidad clínica del trasplante de progenitores hematopoyéticos de donantes alternativos en pacientes con hemopatías malignas

  2019cites this paper
• Mechanisms of Graft-versus-Host Disease Prevention by Post-transplantation Cyclophosphamide: An Evolving Understanding

  2019cites this paper
• Short-term KRP203 and posttransplant cyclophosphamide for graft-versus-host disease prophylaxis

  2019cites this paper
• Haploidentical Transplants: Immune Reconstitution With and Without Augmentation Strategies

  2018cites this paper
• Teaching a Young Dog New Tricks: Modifications to the Post-Transplantation Cyclophosphamide Haploidentical Transplantation Platform.

  2018cites this paper
• Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide/Bendamustine in Pediatric and Young Adult Patients with Hematologic Malignancies.

  2018cites this paper
• Ten-year experience of allogeneic haploidentical hematopoietic stem cell transplantation with non-manipulated grafts in children and adolescents with high-risk acute leukemia

  2018cites this paper
• Post-transplant Cyclophosphamide in Haploidentical Transplantation

  2018cites this paper
• Haploidentical Transplantation

  2018influential citation
• Graft Versus Host Disease (GHVD) in Critically Ill Oncologic Patients

  2018cites this paper
• Applications of Haploidentical SCT in Pediatric Patients

  2017cites this paper
• Halfway there: the past, present and future of haploidentical transplantation

  2017cites this paper
• Haploidentical hematopoietic cell transplantation for adult acute myeloid leukemia: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

  2017cites this paper
• Modern approaches to HLA-haploidentical blood or marrow transplantation

  2016cites this paper
• Haploidentical Hematopoietic Stem Cell Transplantation: A Global Overview Comparing Asia, the European Union, and the United States.

  2016cites this paper
• Choice of Unmanipulated T Cell Replete Graft for Haploidentical Stem Cell Transplant and Posttransplant Cyclophosphamide in Hematologic Malignancies in Adults: Peripheral Blood or Bone Marrow—Review of Published Literature

  2016cites this paper
• Reprint of: Haploidentical Hematopoietic Stem Cell Transplantation: A Global Overview Comparing Asia, the European Union, and the United States.

  2016cites this paper
• Overview of the progress on haploidentical hematopoietic transplantation

  2016cites this paper
• Haploidentical Hematopoietic Stem Cell Transplantation as Platform for Post-transplant Cellular Therapy

  2016cites this paper
• Haploidentical transplantation: selecting optimal conditioning regimen and stem cell source.

  2016cites this paper
• Haploidentical bone marrow and stem cell transplantation: experience with post-transplantation cyclophosphamide.

  2016cites this paper
• Comparative Outcomes after Haploidentical or Unrelated Donor Bone Marrow or Blood Stem Cell Transplantation in Adult Patients with Hematological Malignancies.

  2016cites this paper
• Modern approaches to HLA-haploidentical blood or marrow transplantation.

  2016cites this paper
• Haploidentical Donors: Can Faster Transplantation Be Life-Saving for Patients with Advanced Disease?

  2016cites this paper
• HLA-haploidentical stem cell transplantation -current trends and issues-

  2016cites this paper
• Prevention of Acute Graft-Versus-Host Reaction after Allogeneic Unrelated Hematopoietic Stem Cell Transplantation: Comparison of Effectiveness of Treatment Regimens Based on Anti-Thymocyte Globulin and Cyclophosphamide

  2016cites this paper
• Haematology

  2015cites this paper
• Situational aldehyde dehydrogenase expression by regulatory T cells may explain the contextual duality of cyclophosphamide as both a pro-inflammatory and tolerogenic agent

  2015cites this paper
• A maturing understanding of naive T cells.

  2015cites this paper
• An overview of conditioning regimens for haploidentical stem cell transplantation with post‐transplantation cyclophosphamide

  2015cites this paper
• Post-transplant high-dose cyclophosphamide for the prevention of graft-versus-host disease.

  2015influential citation
• Progress in Haploidentical Hematopoietic Stem Cell Transplantation

  2015cites this paper
• HLA-haploidentical stem cell transplantation using posttransplant cyclophosphamide

  2015cites this paper
• "No donor"? Consider a haploidentical transplant.

  2015cites this paper
• Haploidentical Hematopoietic Stem Cell Transplantation as a Platform for Post-Transplantation Cellular Therapy.

  2015cites this paper
• HLA-Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide after Busulfan-Containing Reduced-Intensity Conditioning.

  2015cites this paper
• T-cell replete haploidentical donor transplantation using post-transplant CY: an emerging standard-of-care option for patients who lack an HLA-identical sibling donor

  2014cites this paper
• Wysokie dawki cyklofosfamidu po niemieloablacyjnym haploidentycznym przeszczepieniu komórek krwiotwórczych u dziecka z nawrotową postacią nerwiaka zarodkowego: krok w kierunku rozdzielenia reakcji GVT i GVH

  2014cites this paper
• Pleurisy as a novel clinical manifestation associated with human herpesvirus 6 after unrelated cord blood transplantation

  2014cites this paper
• HAPLOIDENTICAL STEM CELL TRANSPLANTATION: AN OVERVIEW AND PRESENT SCENARIO

  2014cites this paper
• ТРАНСПЛАНТАЦИЯ АЛЛОГЕННОГО КОСТНОГО МОЗГА БЕЗ ПРОВЕДЕНИЯ ПРЕДТРАНСПЛАНТАЦИОННОГО КОНДИЦИОНИРОВАНИЯ С ИСПОЛЬЗОВАНИЕМ ЦИКЛОФОСФАМИДА И МЕЗЕНХИМАЛЬНЫХ СТРОМАЛЬНЫХ КЛЕТОК В КАЧЕСТВЕ ИНДУКЦИИ ТОЛЕРАНТНОСТИ

  2014cites this paper
• Experts’ considerations on HLA‐haploidentical stem cell transplantation

  2014cites this paper
• Haploidentical vs cord blood transplantation for adults with acute myelogenous leukemia.

  2014cites this paper
• Transplantation tolerance: from theory to clinic

  2014cites this paper
• Selective allodepletion: have we finally found the holy grail?

  2013cites this paper
• Progress in haploidentical stem cell transplantation.

  2012cites this paper
• Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation.

  2012cites this paper
• [Advances in haploidentical transplantation in hematological malignancies].

  2012cites this paper
• Treatment of hematological malignancies with nonmyeloablative, HLA-haploidentical bone marrow transplantation and high dose, post-transplantation cyclophosphamide.

  2011cites this paper
• Nonmyeloablative, HLA-haploidentical bone marrow transplantation with high dose, post-transplantation cyclophosphamide

  2011cites this paper
• Advances in haploidentical stem cell transplantation

  2011cites this paper
• Protective Effects of Indomethacin and Cyclophosphamide but Not of Infliximab on Liver Metabolic Changes Caused by Adjuvant-Induced Arthritis

  2011cites this paper
• Preservation of immune repertoire by selective depletion of haploidentical grafts.

  2010cites this paper
• High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation

  2010cites this paper
• HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide.

  2008cites this paper
• Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide.

  2002cites this paper
• Cyclophosphamide and other new agents for the treatment of severe aplastic anemia.

  2000cites this paper
• Cyclophosphamide with Allogeneic Spleen Cells Followed by PrimedMyelosuppressive Treatments in Mice MHC-Mismatched Barriers by the Additional and Skin Allograft Tolerance Across Fully Induction of Permanent Mixed Chimerism and Kikuo

  2000cites this paper
• Allograft tolerance induced by cyclophosphamide without prior inoculation of donor cells--immune suppression and redirection.

  2000cites this paper
• Induction of Permanent Mixed Chimerism and Skin Allograft Tolerance Across Fully MHC-Mismatched Barriers by the Additional Myelosuppressive Treatments in Mice Primed with Allogeneic Spleen Cells Followed by Cyclophosphamide1

  2000cites this paper
• Immunosuppressive Agents: Biologic Effects In Vivo and In Vitro

  1999cites this paper
• Protection against diabetes by MHC heterozygosity and reversal by cyclophosphamide.

  1998cites this paper
• Fractionated dosing of cyclophosphamide for establishing long-lasting skin allograft survival, stable mixed chimerism, and intrathymic clonal deletion in mice primed with allogeneic spleen cells.

  1997cites this paper
• Cyclophosphamide-induced immunological tolerance: an overview.

  1996cites this paper
• [Cyclophosphamide-induced immunological tolerance: an overview].

  1996cites this paper
• The therapeutic effect of a combination of cofpropamine, a caffeine derivative, and cyclophosphamide on the development of adjuvant arthritis of rats and collagen arthritis of mice.

  1996cites this paper
• Immunosuppressive drug therapy of systemic lupus erythematosus.

  1994cites this paper
• Intravenous cyclophosphamide therapy of severe SLE.

  1989cites this paper
• Long-lasting skin allograft tolerance in adult mice induced across fully allogeneic (multimajor H-2 plus multiminor histocompatibility) antigen barriers by a tolerance-inducing method using cyclophosphamide

  1989cites this paper
• Effects of anticancer drugs on the immune system in humans.

  1989cites this paper
• The necessity of both allogeneic antigens and stem cells for cyclophosphamide-induced skin allograft tolerance in mice.

  1989cites this paper
• Characterization and Functions of the Natural Suppressor Cell Systems

  1989cites this paper
• The necessity of both allogeneic antigens and stem cells for cyclophosphamide-induced skin allograft tolerance in mice.

  1988cites this paper